Delaying Prostate-Specific Antigen Progression in Biochemically Recurrent Prostate Cancer: Is It Clinically Meaningful?
Mené sur 503 patients atteints d'un cancer de la prostate sensible à la castration présentant une récidive biochimique, cet essai de phase III évalue l'efficacité, du point de vue de la survie sans progression du PSA, et la toxicité d'une intensification de doses d'une thérapie anti-androgénique avec ou sans apalutamide
Treating prostate cancer with intensified androgen blockade is widely accepted. Adding androgen receptor pathway inhibitors (ARPIs) to a backbone of androgen deprivation therapy (ADT) became standard of care for metastatic castrate-resistant prostate cancer more than a decade ago.1,2 Since then, this intensified approach has improved overall survival (OS) compared with ADT alone in metastatic hormone-sensitive prostate cancer (HSPC) and in selected men with very high-risk localized and/or node-positive prostate cancer receiving radiotherapy (RT).3-7 Given the efficacy of ARPI doublets, it is logical to explore additional applications of this combination.